The HCPLive spondyloarthritis page is a resource for medical news and expert insights on spondylitis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for autoimmune disease, and more.
April 2nd 2024
Exercise was beneficial in functional status for both patients with RA and spondyloarthritis.
Obesity May Exacerbate Psoriatic Arthritis Risks, Limit TNFI Effectiveness
Analysis of patient records from Denmark and Iceland found that obese psoriatic arthritis patients responded less than their lighter counterparts to tumor necrosis factor inhibitors (TNFIs) and that they used such medications for shorter periods of time.
Study Endorses Early TNF Use in Patients with Psoriasis
A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.
Adalimumab: Efficacy and Adverse Effects for Patients with Active Noninfectious Uveitis
The authors say that for uveitis “there is a large unmet medical need" for identifying other therapies. Adalimumab is associated with decreased visual impairment and decreased risk of uveitic flare, but more adverse events, according the results from a recent multinational phase 3 trial.
Trial Shows Ixekizumab Effective Against Psoriatic Arthritis
Ixekizumab patients, who all started with an introductory 160-mg dose, were all more likely than placebo patients to achieve the primary endpoint of the study: a 20% reduction in disease burden as measured by American College of Rheumatology criteria (an ACR20 response) by week 24.
Jerry Bagel, MD, Explains How to Measure Success in Psoriasis Treatment
As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.
Jerry Bagel, MD: Evolution of Psoriasis Treatment Means Better Results for Patients
As new treatments for plaque psoriasis are developed the field as a whole is taking a new look at the condition. However, there are still challenges to overcome in diagnosis and treatment.
Biosimilar of Enbrel, a Popular Arthritis and Inflammation Drug, Receives FDA Approval
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product†while demonstrating “clinically meaningful differences in terms of safety and effectiveness.â€
Golimumab Effective Against Uveitis Associated with Ankylosing Spondylitis
Retrospective study results indicate that golimumab may be a new and effective choice for maintaining remission and preventing recurrence of severe, recurrent anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis.
Study Shows TNF Inhibitors Prevent Relapse of Uveitis in Most Patients with Ankylosing Spondylitis
Adalimumab, infliximab, and etanercept, reduced the number of uveitis relapses in a retrospective, long-term study of uveitis patients with HLA-B27-positive ankylosing spondylitis who had taken one of these biological agents for at least 1 year.
Study Offers New Treatment Possibilities for Rheumatic Pain Sufferers
Enthesitis refers to the instance of inflammation at the point where a tendon joins to a bone. Looking for further insight into the mechanisms behind inflammatory rheumatism, researchers from delved into the roots of Achilles enthesitis and may have emerged with a new approach to treating many rheumatic conditions.
Psoriasis Severity Escalates Risk for Aortic Aneurysm
While it has been known for some time that psoriasis patients are at increased risk of developing cardiovascular disease and other comorbidities, new research has shown that these patients also have a higher risk of developing aortic aneurysms.
Most Patients with Plaque Psoriasis Are Dissatisfied with Their Treatment
Many psoriasis patients wish they were better informed of the significant impact their skin condition would have on their physical and mental health, according to results from Psoriasis in America 2016, a Health Union national survey.
Is All Inflammation the Same? Study Looks at Similarities, Differences in Treatment
Patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis still face challenges research has yet to meet, according to the authors: “Given the commonality of comorbidities across all three diseases, there is a degree of overlap in their management.â€
Analysis of data from 2 large trials finds that cutoffs used to separate different “disease activity states†on the Disease Activity index for Psoriatic Arthritis (DAPSA) are valid. Different disease activity states are associated with different degrees of functional impairment and joint damage progression.
Biosimilar Drugs for Psoriatic Arthritis, Other Conditions, One Step Closer to Approval
The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).